Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Apoptosis-related gene expression in benign prostatic hyperplasia and prostate carcinoma.

Iacopino F, Angelucci C, Lama G, Zelano G, La Torre G, D'Addessi A, Giovannini C, Bertaccini A, Macaluso MP, Martorana G, Sica G.

Anticancer Res. 2006 May-Jun;26(3A):1849-54.

2.

Bcl-2 and bax expression and prostate cancer outcome in men treated with radiotherapy in Radiation Therapy Oncology Group protocol 86-10.

Khor LY, Desilvio M, Li R, McDonnell TJ, Hammond ME, Sause WT, Pilepich MV, Okunieff P, Sandler HM, Pollack A.

Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):25-30. Epub 2006 Jul 11.

3.

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.

Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, Sandler H.

Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):965-74.

PMID:
16798415
4.

Androgen and its receptor promote Bax-mediated apoptosis.

Lin Y, Kokontis J, Tang F, Godfrey B, Liao S, Lin A, Chen Y, Xiang J.

Mol Cell Biol. 2006 Mar;26(5):1908-16.

5.

Antisense Bcl-2 sensitizes prostate cancer cells to radiation.

Mu Z, Hachem P, Pollack A.

Prostate. 2005 Dec 1;65(4):331-40.

6.

Immunohistochemical expression of Bax and Bcl-2 in penile carcinoma.

Saeed S, Keehn CA, Khalil FK, Morgan MB.

Ann Clin Lab Sci. 2005 Winter;35(1):91-6.

PMID:
15830715
7.

Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02.

Pollack A, DeSilvio M, Khor LY, Li R, Al-Saleem TI, Hammond ME, Venkatesan V, Lawton CA, Roach M 3rd, Shipley WU, Hanks GE, Sandler HM.

J Clin Oncol. 2004 Jun 1;22(11):2133-40.

PMID:
15169799
8.

Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.

Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, Horwitz EM, Lawton C, Rosenthal SA, Sandler HM, Shipley WU; Radiation Therapy Oncology Group.

J Clin Oncol. 2003 Nov 1;21(21):3972-8. Erratum in: J Clin Oncol. 2004 Jan 15;22(2):386.

PMID:
14581419
9.

Bcl-2 is significantly overexpressed in localized radio-recurrent prostate carcinoma, compared with localized radio-naive prostate carcinoma.

Rosser CJ, Reyes AO, Vakar-Lopez F, Levy LB, Kuban DA, Hoover DC, Lee AK, Pisters LL.

Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):1-6.

PMID:
12694817
10.

Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x.

Pollack A, Cowen D, Troncoso P, Zagars GK, von Eschenbach AC, Meistrich ML, McDonnell T.

Cancer. 2003 Apr 1;97(7):1630-8.

11.

Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer.

Zellweger T, Ninck C, Mirlacher M, Annefeld M, Glass AG, Gasser TC, Mihatsch MJ, Gelmann EP, Bubendorf L.

Prostate. 2003 Apr 1;55(1):20-9.

PMID:
12640657
12.

Regulation of Bcl-2 during androgen-unresponsive progression of prostate cancer.

Rothermund CA, Kondrikov D, Lin MF, Vishwanatha JK.

Prostate Cancer Prostatic Dis. 2002;5(3):236-45.

13.

bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with rectal cancer.

Scopa CD, Vagianos C, Kardamakis D, Kourelis TG, Kalofonos HP, Tsamandas AC.

Appl Immunohistochem Mol Morphol. 2001 Dec;9(4):329-34.

PMID:
11759059
14.

Apoptosis and bcl-2 expression in prostate cancer: significance in clinical outcome after brachytherapy.

Szostak MJ, Kaur P, Amin P, Jacobs SC, Kyprianou N.

J Urol. 2001 Jun;165(6 Pt 1):2126-30.

PMID:
11371940
15.

Adenovirus-mediated Bax overexpression for the induction of therapeutic apoptosis in prostate cancer.

Li X, Marani M, Yu J, Nan B, Roth JA, Kagawa S, Fang B, Denner L, Marcelli M.

Cancer Res. 2001 Jan 1;61(1):186-91.

16.

Immunohistochemical Analysis of Radical Prostatectomy Specimens After 8 Months of Neoadjuvant Hormonal Therapy.

Paterson RF, Gleave ME, Jones EC, Zubovits JT, Goldenberg SL, Sullivan LD.

Mol Urol. 1999;3(3):277-286.

PMID:
10851334
17.

The impact of bcl-2 expression and bax deficiency on prostate homeostasis in vivo.

Bruckheimer EM, Cho S, Brisbay S, Johnson DJ, Gingrich JR, Greenberg N, McDonnell TJ.

Oncogene. 2000 May 11;19(20):2404-12.

18.

Apoptosis, mitosis, p53, bcl(2), Ki-67 and clinical outcome in prostate carcinoma treated by androgen ablation.

Szende B, Romics I, Torda I, Bély M, Szegedi Z, Lovász S.

Urol Int. 1999;63(2):115-9.

PMID:
10592500
20.

Supplemental Content

Support Center